Kelly Konopa, MD
Hematology & Oncology · Salt Lake City, UTNPI 1033272489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $156 and has fallen 88.6% since, to $18 in 2025. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 13 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$48
- AstraZeneca$39
- Johnson & Johnson$37
- Gilead$25
- Agios Pharmaceuticals, Inc.$16
- Servier Pharmaceuticals LLC$15
- plus $27 from 2 others
What the payments were for
- Food & beverage$207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $48 |
| AstraZeneca(2 entities) | 3 | $39 |
| Johnson & Johnson | 2 | $37 |
| Gilead | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
How this compares
$207 in reported general payments places this provider in the 15th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.